

## BC Cancer Extravasation Hazard Table

VESICANT	NONVESICANT	
	IRRITANT	NONE
amsacrine busulfan carmustine DACTINomycin DAUNOrubicin DOXOrubicin epirubicin IDArubicin mechlorethamine melphalan mitomycin streptozocin vinBLAStine vinCRIStine vindesine vinorelbine	arsenic azaCITIDine bendamustine bortezomib CISplatin dacarbazine DOCEtaxel DOXOrubicin pegylated liposomal etoposide fluorouracil gemcitabine ifosfamide mesna (undiluted) mitoXANTRONE *oxaliplatin *PACLitaxel *PACLitaxel-nab porfimer temozolomide teniposide trastuzumab emtansine (KADCYLA®)	aldesleukin alemtuzumab amifostine asparaginase avelumab BCG bevacizumab bleomycin blinatumomab brentuximab vedotin buserelin cabazitaxel CARBOplatin carfilzomib cetuximab cladribine clodronate cyclophosphamide cytarabine degarelix dexrazoxane eriBULin fludarabine  goserelin interferon ipilimumab irinotecan leucovorin leuprolide mesna (diluted) methotrexate octreotide oBINutuzumab nivolumab pamidronate PANitumumab pembrolizumab pemetrexed PERTuzumab plerixafor ramucirumab raltitrexed riTUXimab romiDEPsin temsirolimus testosterone thiotepa topotecan trastuzumab (HERCEPTIN®) zoledronic acid

\*Follow guidelines and treat like a vesicant.

For definitions of different categories of extravasation hazard and the details on management of extravasation, see [BC Cancer Systemic Therapy Policy III-20](#).